Home > others & > CX-3543

CX-3543

Quarfloxin,CX 3543,CX3543

CX-3543 is a fluoroquinolone derivative with antineoplastic activity. Quarfloxin disrupts the interaction between the nucleolin protein and a G-quadruplex DNA structure in the ribosomal DNA (rDNA) template, a critical interaction for rRNA biogenesis that is overexpressed in cancer cells; disruption of this G-quadruplex DNA:protein interaction in aberrant rRNA biogenesis may result in the inhibition of ribosome synthesis and tumor cell apoptosis.

目录号
EY2044
EY2044
纯度
99.28%
99.28%
规格
1 mg
5 mg
原价
1450
2960
售价
1450
2960
库存
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    CX-3543 is a fluoroquinolone derivative with antineoplastic activity. Quarfloxin disrupts the interaction between the nucleolin protein and a G-quadruplex DNA structure in the ribosomal DNA (rDNA) template, a critical interaction for rRNA biogenesis that is overexpressed in cancer cells; disruption of this G-quadruplex DNA:protein interaction in aberrant rRNA biogenesis may result in the inhibition of ribosome synthesis and tumor cell apoptosis.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Drygin D.et al. Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis.Cancer Res. 2009 Oct 1;69(19):7653-61. doi: 10.1158/0008-5472.CAN-09-1304.

    分子式
    C35H33FN6O3    		 分子量
    604.67    		 CAS号
    865311-47-3    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    20 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT00955786 Advanced Solid Tumors|Lymphoma Drug: CX-3543 Cylene Pharmaceuticals Phase 1 2005-07-01 2009-08-07
    NCT00780663 Neuroendocrine Tumors|Carcinoid Tumor Drug: Quarfloxin Cylene Pharmaceuticals Phase 2 2008-10-01 2011-06-13
    NCT00485966 B-Cell Chronic Lymphocytic Leukemia Drug: CX-3543 Cylene Pharmaceuticals Phase 2 2007-06-01 2008-11-03
    NCT00955292 Advanced Solid Tumors|Lymphoma Drug: Quarfloxin Cylene Pharmaceuticals Phase 1 2007-07-01 2009-08-07

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：